• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    India’s New Medical Devices Rules

    Discovering Packaging’s Hidden Value

    Deliberate Disposal: Single-Use & Disposables Technologies

    Illuminating Tubing’s Future

    Positive Identification: An Examination of Converting, Labeling, and Printing
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Technology Used to Map Mars Measures Treatment's Effect on Tumors

    Glowing Contact Lens Could Prevent Leading Cause of Diabetic Blindness

    Positive Late-Breaking Data Unveiled for Boston Scientific's Deep Brain Stimulation Study

    Medtronic's IN.PACT Admiral Drug-Coated Balloon Approved to Treat Long SFA Lesions

    Space Station Robotic Arm Tech Revolutionizes Neurosurgery at Henry Ford Hospital
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    India’s New Medical Devices Rules

    Discovering Packaging’s Hidden Value

    Deliberate Disposal: Single-Use & Disposables Technologies

    Illuminating Tubing’s Future

    Positive Identification: An Examination of Converting, Labeling, and Printing
    Top 30 Medical Device Companies
    Top Top 30
    Top 30 Global Medical Device Companies

    1. Medtronic plc

    2. Johnson & Johnson

    3. GE Healthcare

    4. Siemens Healthineers
    Market Data
    Datawatch Column
    Salary Survey
    White Papers
    Top Research
    Extolling the Virtues of Surgical Simulation

    Will Medtech M&A Mania Continue?

    Learn from My Mistakes: Why You Need a Quality System

    Brexit: D-Day or the Y2K for Global Supply Chains?

    Planning for Brexit
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    American Kuhne, a brand of Graham Engineering Corp.

    Teel Plastics

    GeoTec

    Needle Specialty Products Corporation

    Swiss Automation Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    Slideshows
    Top Resources
    Single-Use Device Reprocessing Tailwinds and Headwinds

    Healthcare Artificial Intelligence Market to Register Commendable 40 Percent CAGR Over 2017-2024

    Finding Talent in Healthcare IoT

    Transforming from Supplier to Partner

    Building a Better Package
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Salary Survey
      • Market Data
      • Datawatch Column
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Four Common Misperceptions of Accelerated FDA Approval

    The 21st Century Cures Act aims to spur medical innovation such as “smart” drugs, which use nanotechnology for effective delivery and control of side effects.
    The 21st Century Cures Act aims to spur medical innovation such as “smart” drugs, which use nanotechnology for effective delivery and control of side effects.
    Related CONTENT
    • Senate Passage of 21st Century Cures Act a Win for Patients, Innovation
    • FDA Warns of Potential Fires and Explosions From Battery-Powered Medical Carts
    • New Year’s Resolutions for Industry
    • FDA Clears Voxello's Speech Generation Device
    • Precision-Based Tech Changing Cancer Detection and Treatment
    Matthew M. Lowe, Executive Vice President, MasterControl03.07.17
    The 21st Century Cures Act addresses a wide range of healthcare issues, from opioid-abuse prevention to the need for interoperability of electronic health records. Some of the biggest criticisms of the law, however, focused on provisions intended to accelerate the approval of medical products by the U.S. Food and Drug Administration (FDA).

    When it comes to FDA approval processes, the situation is a classic Catch-22. The public wants cheaper medical products sooner. Yet critics sounded the alarm bells when the legislation—which promises a faster approval process that could potentially lower development costs—was signed into law in December 2016.

    Some of the most spirited arguments against the law center on four provisions1 designed to streamline the drug and medical device development and approval processes. These provisions are also the most commonly misunderstood. The first two are specifically targeted toward the medical device sector.

    #1 Section 3051: Breakthrough Devices
    The new law allows the FDA to prioritize approval of medical devices that represent breakthrough technologies. The agency is required to create a guidance that will identify the criteria and the processes for devices designated for expedited development and priority review.

    Misperception: Some people think this creates overly broad standards and sets the bar too low for what are considered “breakthrough” devices. They are afraid this provision might pressure the FDA to hasten the approval process, which could result in poor decisions and less-than-safe devices.
    In fact, this provision will increase the efficiency of the process for reviewing devices for life-threatening diseases or irreversibly debilitating conditions—when there are no other device alternatives.

    First, medtech firms are aware that for their products to qualify as breakthrough devices, they must offer substantial advantages over any existing or similar devices. Critics ought to realize that providing such proof is a heavy burden, making it unlikely for manufacturers to apply for priority review willy-nilly.

    Second, critics should realize that a similar process already exists and the world hasn’t stopped spinning. Section 3051 simply builds on the FDA’s Expedited Access Pathway (EAP)2 for devices that address “unmet medical needs” of patients suffering life-threatening diseases. The FDA has granted 24 devices access to this innovative program, which marked its first full year of operation in 2016.3

    Third, I have always been a huge proponent of giving patients with a terminal condition the choice when it comes to taking on risk with new and developing technologies. Most of these patients have tried everything to no avail, so how can we deny them the hope from potentially breakthrough alternatives? Most of them want to help in accelerating data collection for future patients with the same condition. Ultimately, this means they are taking an active role in their own treatment. If I were in their situation, I know I would want to have a choice.

    #2 Section 2058: Least Burdensome Device Review
    The 21st Century Cures Act provides that FDA employees involved in the review of premarket submissions for devices should apply the “least burdensome requirements.”

    Misperception: Critics think this will divert FDA employee focus away from the safety and efficacy standards of devices, and therefore make the review process less effective.

    Pundits outside the life science industry don’t realize that the “least burdensome” requirement has always been in place. It is neither new nor harmful.

    “Least burdensome” means the minimum required to show effectiveness, but as medtech veterans know, in practice the situation is much stricter. Medical device firms jump through regulatory hoops that can only be characterized as the opposite of “least burdensome.”

    What the new law adds is the requirement that FDA employees be trained properly regarding the meaning and implementation of “least burdensome requirements” and to ensure that they apply the principle consistently. The law calls for a periodic assessment of employee training and requires the FDA ombudsman to conduct an audit to make sure this provision is being followed.

    #3 Section 3022: Real World Evidence
    Real world evidence (RWE) refers to data regarding usage of a drug from sources other than randomized clinical trials, such as ongoing safety surveillance, observational studies, registries, claims, and patient-centered outcomes research activities.

    Misperception: The nonprofit advocacy group Public Citizen4 fears the law will weaken the FDA standards for product approval and lower the bar for the type of evidence needed to comply with post-approval requirements.

    In fact, the new law neither mandates the FDA to use RWE nor changes the agency’s gold standard of approval based on randomized clinical trials, which has been in place since 1962.5 It merely allows the use of real world evidence in some cases, which, if combined with post-approval studies, could accelerate the review process.

    It’s only common sense to use real world evidence. If you are just going for another indication or an expanded indication, why wouldn’t you leverage data from the therapy that is already out in the market? Why replicate safety data for a therapy already in widespread use? This is costly, a waste of time, and delays a new therapy from reaching the market in a timely manner. What’s truly astonishing is the fact that we haven’t been doing this before. No wonder it costs so much to develop a drug in the United States.

    Within two years, the FDA must establish a guidance and a framework for implementing this provision. It must consult with stakeholders, including industry and patient advocacy groups, for the potential use of RWE.

    Dr. Robert Califf, former FDA commissioner, points out that randomized clinical trials and real world evidence are not incompatible. “In fact, the use of randomization within the context of clinical practice will constitute a major advance in evidence generation and we are actively encouraging proposals with this combination of randomized trials conducted in real world practice,” said Dr. Califf.3

    #4 Section 3031: Summary Level Review
    Summary level review refers to “a summary of clinical data that demonstrates the safety and effectiveness of a drug with respect to a qualified indication” to be used to support the approval of a supplemental application. A supplemental application is eligible for review if there is existing data available demonstrating the safety of the drug.

    Misperception: Critics think this section, like real world evidence, will dilute  FDA standards for approving supplemental new drug applications.

    First, when a drug has been approved, it means it has been tested for safety in a healthy patient population. The new law allows the drug manufacturer to leverage that data to obtain another indication for the same drug. It doesn’t make sense to repeat the safety testing, because the data generated will be the same. Repetition only delays getting the new indication to patients and costs millions of dollars that are simply wasted.

    Second, this provision doesn’t mean the FDA cannot or will not ask for full data if necessary. The law allows summary level review, but it doesn’t stop the FDA from asking for full data. The term “qualified indication” implies a built-in screening process, because only indications deemed by the FDA as qualified can take advantage of this provision.

    The FDA is required to be transparent about its use of this provision. It will post the number of applications reviewed and the average time of review, among other things, on the agency’s website.

    Other Misperceptions
    Perhaps the biggest misperception is that the aforementioned provisions are new and untried ideas. In fact, they came from the ongoing efforts of the FDA, the life science industry, advocacy groups, and other stakeholders to improve the approval processes. They build on current efforts to include more patient input in the development process. The provision pertaining to “breakthrough devices,” just like the EAP, gives the patient a voice in the FDA’s decision-making process.

    It took two years and more than 900 pages to finalize the 21st Century Cures Act. It is estimated to cost $6.3 billion upon implementation. It is far from perfect. There is a lot more that the government and the industry must do to accelerate product approval and support medical innovation.

    At the same time, we have to appreciate the law’s ambition and scope, and the great effort in gathering input from stakeholders through the numerous hearings. Most of all, we should appreciate the fact that the new law keeps the ball moving forward in terms of the one thing everybody wants—optimizing, streamlining, and accelerating the FDA review and approval processes—in order to deliver the medical products and treatments to patients sooner rather than later. 

    References
    1. 21st Century Cures Act: http://bit.ly/21curesact.
    2. FDA’s Expedited Access Pathway Program: http://bit.ly/fdaeapp.
    3. “21st Century Cures Act: Making Progress on Shared Goals for Patients,” by FDA Commissioner Robert M. Califf, FDA Voice Blog, Dec. 13, 2016. http://bit.ly/mpo031710.
    4. From Public Citizen’s website: http://bit.ly/mpo031711.
    5. The 1962 Drug Amendments (also known as Kefauver-Harris Amendments), which included GMP requirements, required manufacturers to prove that their products are safe before selling them. The law toughened up FDA inspections and required the reporting of adverse side effects.

    Matthew M. Lowe, executive vice president at MasterControl, is the author of “Convergence of Compliance and Technology: How Technology Has Changed Regulatory Compliance in the Past Decade” (http://bit.ly/mpo031712). He is a mechanical engineer with over a dozen years of medical device experience in product development, product management, and regulatory compliance. He has successfully launched more than a dozen medical devices and has five patents issued. His regulatory compliance experience includes writing a 510(k) that was cleared by the FDA and managing a multisite, multiyear postmarket clinical study for orthopedic devices. 
    Related Searches
    • healthcare
    • dr
    • orthopedic
    • data
    Related Knowledge Center
    • Cardiovascular
    • Digital Health
    • Diagnostics
    Suggested For You
    Industry Offers Support for Gottlieb Confirmation Industry Offers Support for Gottlieb Confirmation
    Four Takeaways from Recent Regulatory Audit Changes Four Takeaways from Recent Regulatory Audit Changes
    FDA Designates N8 Medical FDA Designates N8 Medical's CeraShield Endotracheal Tube as a Breakthrough Device
    FDA Clears First Whole Slide Imaging System for Digital Pathology FDA Clears First Whole Slide Imaging System for Digital Pathology
    Collaborating on Custom Materials Development Collaborating on Custom Materials Development
    Extractable/Leachable Chemistry Testing Strategies for Medical Devices Extractable/Leachable Chemistry Testing Strategies for Medical Devices
    Senate Bill Would Improve Medicare LCD Process Senate Bill Would Improve Medicare LCD Process
    First in Man First in Man
    In Pursuit of Device Safety or a Call for Whistleblowers? In Pursuit of Device Safety or a Call for Whistleblowers?
    FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device
     FlowAid Receives FDA Clearance for the FA100 SCCD FlowAid Receives FDA Clearance for the FA100 SCCD
    Mike on Medtech: Real World Evidence Mike on Medtech: Real World Evidence
    Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use
    Precision-Based Tech Changing Cancer Detection and Treatment Precision-Based Tech Changing Cancer Detection and Treatment
    FDA Clears Voxello FDA Clears Voxello's Speech Generation Device

    Related Columns

    • Software & IT | Surgical
      Extolling the Virtues of Surgical Simulation

      Extolling the Virtues of Surgical Simulation

      Gaining surgical competence for a new technique has a drastic learning curve. When surgeons are trained to perform a new procedure, however, the curriculum appears remarkably straightforward. Typically, the surgeon will attend a one- or two-day cours…
      Sam Brusco, Associate Editor 04.03.18

    • Neurological
      The Development of New Medtech Markets Through Neurostimulation

      The Development of New Medtech Markets Through Neurostimulation

      The number of new disease states that can be addressed with implantable neurostimulation devices continues to grow.  The most common currently indicated use for these technologies is for the treatment of chronic pain—an enormous market tha…
      Maria Shepherd, President and Founder, Medi-Vantage 03.15.18

    • Cardiovascular | Digital Health
      Feeding the Medtech Innovation Pipeline

      Feeding the Medtech Innovation Pipeline

      MassMEDIC is the largest regional medical device association in the United States, with member companies ranging from the largest to the smallest medical technology innovators. The MassMEDIC Medtech Showcase, held in October every year, is a meeting…
      Maria Shepherd, President and Founder, Medi-Vantage 01.30.18


    • Digital Health
      Medtech Is Dead if It Is Resistant to Change

      Medtech Is Dead if It Is Resistant to Change

      MedtechVision2017 isn’t your average “women in medtech” meeting. The founders (www.medtechwomen.org) demand (and receive) the best content from their all-volunteer team of meeting planners and visionaries. This year’s event&md…
      Maria Shepherd, President and Founder, Medi-Vantage 10.05.17

    • Digital Health
      The Future of Artificial Intelligence and Quality Management

      The Future of Artificial Intelligence and Quality Management

      Industry leaders are required to keep up with change. In regulated industries like the life sciences, ensuring the safety of all products—and therefore, the public—is a main priority. Change is the necessary component driving continuous i…
      Emily Ysaguirre, Content Marketing Writer, EtQ 10.05.17

    • Diagnostics | R&D & Design
      Designing Diagnostic Consumables: Custom or Off-the-Shelf?

      Designing Diagnostic Consumables: Custom or Off-the-Shelf?

      Designing point-of-care diagnostic cartridges has always been a custom affair. Specialized designers and engineers use know-how in assay development, microfluidics, and systems engineering to develop a product from top to bottom. The result is a cust…
      Steve Maylish, Fusion Biotec, and Richard Spero, Redbud Labs 10.05.17


    • Cardiovascular | Surgical
      Age of Innovation for Valves

      Age of Innovation for Valves

      By the time one reaches age 75, each of his or her four heart valves will have opened and closed approximately 3 billion times. But aging and illness cause some heart valves to stiffen or flop. Although mild valve damage may be treated with medicatio…
      David Novotny, Novella Clinical 09.01.17

    • Diagnostics | Surgical
      Crash Test Dummies with Synthetic Beating Hearts

      Crash Test Dummies with Synthetic Beating Hearts

      Tampa, Fla.-based SynDaver Labs is in the business of manufacturing humans. But before you grab your torch and pitchfork and race off to rally the townspeople, they’re not live humans and are most certainly not harvested from graveyards by a ma…
      Sam Brusco, Associate Editor 07.26.17

    • Cardiovascular | Diagnostics
      Changing Administrations and the Strategy for Value-Based Growth in Medtech

      Changing Administrations and the Strategy for Value-Based Growth in Medtech

      In 2013, the U.S. medtech business turned the corner with improving revenue trends. The roll-out of Obamacare has stimulated growth in hospital admissions and other new systems of healthcare utilization at sites of care that didn’t exist before…
      Maria Shepherd, Medi-Vantage 07.26.17


    • Diagnostics | Digital Health | Patient Monitoring
      Medical Auto-Pilot: Medtech’s Focus on Digital Therapeutics

      Medical Auto-Pilot: Medtech’s Focus on Digital Therapeutics

      Necessity is the mother of invention. Although often attributed to Plato and appearing in certain translations of his Republic, this well-known proverb more likely evolved from an early 1500s Latin textbook of everyday sayings that included the phras…
      Bryan Hughes, Director, P&M Corporate Finance 07.26.17

    • Digital Health | Software & IT | Testing
      Recent Cyber Attack Enough to Make Medtech WannaCry

      Recent Cyber Attack Enough to Make Medtech WannaCry

      It was the U.S. Food and Drug Administration’s (FDA) worst nightmare come true. On May 12, the WannaCry ransomware cryptoworm slithered its way into computers worldwide, infecting as many as 200,000 Microsoft Windows systems in 150 countries…
      Michael Barbella, Managing Editor 06.06.17

    • Diagnostics | Digital Health | Electronics | Patient Monitoring
      The Future of Medical Wearables

      The Future of Medical Wearables

      The wearables market is expected to reach over $4 billion in 2017.1 If that doesn’t paint the picture for a bright future, consider this: one in six consumers currently own and use wearable tech.2 Clearly, the wearables market is exploding and…
      Mike Bolduc, Global Marketing Manager, Industrial and Medical Segments, C&K 06.06.17

    • Electronics | Materials | Neurological
      Graphene on My Mind

      Graphene on My Mind

      Scientists are beginning to run out of superlatives for graphene, the two-dimensional wonder material. It’s been hailed as the lightest, strongest, thinnest, and best heat- and electricity-conducting material ever discovered. Similar to the pla…
      Sam Brusco, Associate Editor 05.01.17

    • Diagnostics | Digital Health | Electronics | Patient Monitoring | Software & IT
      Boldly Entering Healthcare’s Final Frontier

      Boldly Entering Healthcare’s Final Frontier

      Chances are the 21st-century tricorder will look radically different than its fictional 2260s-era counterpart. Foremost, it won’t be as large or bulky as the Hollywood version, nor will it resemble an old-fashioned radio or small portable te…
      Michael Barbella, Managing Editor 04.03.17

    • Diagnostics
      An Update on the In Vitro Diagnostics Sector

      An Update on the In Vitro Diagnostics Sector

      High-profile product launches, resounding clinical data, the U.S. government investment in the Precision Medicine program, and multiple billion-dollar acquisitions are hallmarks of the diagnostics industry. Equally notable was the surprising decision…
      Maria Shepherd, President and Founder, Medi-Vantage 04.03.17


    Breaking News
    • Technology Used to Map Mars Measures Treatment's Effect on Tumors
    • Glowing Contact Lens Could Prevent Leading Cause of Diabetic Blindness
    • Positive Late-Breaking Data Unveiled for Boston Scientific's Deep Brain Stimulation Study
    • Medtronic's IN.PACT Admiral Drug-Coated Balloon Approved to Treat Long SFA Lesions
    • Space Station Robotic Arm Tech Revolutionizes Neurosurgery at Henry Ford Hospital
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • India’s New Medical Devices Rules
    • Discovering Packaging’s Hidden Value
    • Deliberate Disposal: Single-Use & Disposables Technologies
    • Illuminating Tubing’s Future
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.